Cargando…

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma

PURPOSE: Although recent data from the literature suggest that PET imaging with [18]-Fluorodeoxyglucose ((18)F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker in many laboratories for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailly, Clément, Gouard, Sébastien, Lacombe, Marie, Remaud-Le Saëc, Patricia, Chalopin, Benjamin, Bourgeois, Mickaël, Chouin, Nicolas, Tripier, Raphaël, Halime, Zakaria, Haddad, Ferid, Faivre-Chauvet, Alain, Kraeber-Bodéré, Françoise, Chérel, Michel, Bodet-Milin, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823645/ https://www.ncbi.nlm.nih.gov/pubmed/29507674 http://dx.doi.org/10.18632/oncotarget.23886

Ejemplares similares

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
por: Bailly, Clément, et al.
Publicado: (2019)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
por: Gouard, Sébastien, et al.
Publicado: (2020)

Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with (18)FDG PET-CT
por: Foubert, Fanny, et al.
Publicado: (2018)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

Interest of Pet Imaging in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2019)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials
por: Bailly, Clément, et al.
Publicado: (2016)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

ImmunoPET to help stratify patients for targeted therapies and to improve drug development
por: Kraeber-Bodere, Françoise, et al.
Publicado: (2016)

Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
por: Bodet-Milin, Caroline, et al.
Publicado: (2019)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma
por: Bailly, Clement, et al.
Publicado: (2017)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy
por: Bailly, Clément, et al.
Publicado: (2014)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
por: Bodet-Milin, Caroline, et al.
Publicado: (2023)

Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
por: Pallardy, Amandine, et al.
Publicado: (2020)

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases
por: Pichon, Baptiste, et al.
Publicado: (2020)

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
por: Carlier, Thomas, et al.
Publicado: (2013)

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
por: Rousseau, Caroline, et al.
Publicado: (2011)

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
por: Carlier, Thomas, et al.
Publicado: (2020)

Preclinical Evaluation of a (64)Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
por: Métivier, Cassandra, et al.
Publicado: (2023)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
por: Bailly, Clément, et al.
Publicado: (2019)

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety
por: Delage, Judith Anna, et al.
Publicado: (2021)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Pilot Study of (64)CuCl(2) for PET Imaging of Inflammation
por: Jiang, Lei, et al.
Publicado: (2018)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
por: Goulon, Dorothée, et al.
Publicado: (2016)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v0ug7mcd2v6l01p4de7nrk8pk2